Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 7
1997 3
1998 7
1999 5
2000 7
2001 11
2002 11
2003 17
2004 16
2005 6
2006 9
2007 21
2008 13
2009 9
2010 5
2011 11
2012 10
2013 14
2014 12
2015 13
2016 13
2017 18
2018 10
2019 5
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

224 results
Results by year
Filters applied: . Clear all
Page 1
Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial
Chagas MH, et al. J Psychopharmacol 2014 - Clinical Trial. PMID 25237116
Although no neuroprotective treatments for PD have been found to date, the endocannabinoid system has emerged as a promising target. ...One week before the trial and in the last week of treatment participants were assessed in respect to (i) motor and general symptoms score (UPDRS); (ii) well-being and quality of life (PDQ-39); and (iii) possible neuroprotective effects (BDNF and H(1)-MRS). ...
Although no neuroprotective treatments for PD have been found to date, the endocannabinoid system has emerged as a promising target. …
Neuroprotective and disease-modifying effects of the ketogenic diet.
Gasior M, et al. Behav Pharmacol 2006 - Review. PMID 16940764 Free PMC article.
These observations are supported by studies in animal models and isolated cells that show that ketone bodies, especially beta-hydroxybutyrate, confer neuroprotection against diverse types of cellular injury. ...Although the mechanisms are not yet well defined, it is plausible that neuroprotection results from enhanced neuronal energy reserves, which improve the ability of neurons to resist metabolic challenges, and possibly through other actions including antioxidant and anti-inflammatory effects. ...
These observations are supported by studies in animal models and isolated cells that show that ketone bodies, especially beta-hydroxybutyrat …
Melatonin Pharmacokinetics Following Oral Administration in Preterm Neonates
Carloni S, et al. Molecules 2017. PMID 29194416 Free PMC article.
Blood samples were collected before and at selective times after melatonin administration. The half-life of melatonin in plasma ranged from 7.98 to 10.94 h, and the area under the curve (AUC) from 10.48 to 118.17 µg·mL(-1)·h(-1). ...
Blood samples were collected before and at selective times after melatonin administration. The half-life of melatonin in plasma range
Determination of permeability, plasma protein binding, blood partitioning, pharmacokinetics and tissue distribution of Withanolide A in rats: A neuroprotective steroidal lactone.
Singh SK, et al. Drug Dev Res 2018. PMID 30284738
In this study, we investigated the permeability, plasma protein binding (PPB), blood partitioning, intravenous (i.v.), and oral pharmacokinetics as well as i.v. tissue distribution (TD) of pure WA in a rat model. ...
In this study, we investigated the permeability, plasma protein binding (PPB), blood partitioning, intravenous (i.v.), and oral pharm …
Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis.
Crowther CA, et al. PLoS Med 2017. PMID 28976987 Free PMC article.
Studies were identified based on the Cochrane Pregnancy and Childbirth search strategy using the terms [antenatal or prenatal] and [magnesium] and [preterm or premature or neuroprotection or 'cerebral palsy']. ...CONCLUSIONS: Antenatal magnesium sulphate given prior to preterm birth for fetal neuroprotection prevents CP and reduces the combined risk of fetal/infant death or CP. ...
Studies were identified based on the Cochrane Pregnancy and Childbirth search strategy using the terms [antenatal or prenatal] and [magnesiu …
High-Dose Cannabidiol Induced Hypotension after Global Hypoxia-Ischemia in Piglets
Garberg HT, et al. Neonatology 2017. PMID 28564654
OBJECTIVE: To assess the safety and potential neuroprotective effects of high-dose CBD. METHODS: Anesthetized newborn piglets underwent global HI by ventilation with 8% O2 until the point of severe metabolic acidosis (base excess -20 mmol/L) and/or hypotension (mean arterial blood pressure ≤20 mm Hg). ...CONCLUSIONS: High-dose CBD can induce severe hypotension and did not offer neuroprotection in the early phase after global HI in piglets....
OBJECTIVE: To assess the safety and potential neuroprotective effects of high-dose CBD. METHODS: Anesthetized newborn piglets underwe …
Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial
Fouda AY, et al. Stroke 2017 - Clinical Trial. PMID 28887388
Concentrations remained at neuroprotective levels (>3 mg/L) throughout the dosing interval in 5 of 7 patients. CONCLUSIONS: In intracerebral hemorrhage, a 400 mg dose of minocycline was safe and achieved neuroprotective serum concentrations. ...
Concentrations remained at neuroprotective levels (>3 mg/L) throughout the dosing interval in 5 of 7 patients. CONCLUSIONS: In int …
Selected B vitamins and their possible link to the aetiology of age-related sarcopenia: relevance of UK dietary recommendations
Aytekin N, et al. Nutr Res Rev 2018 - Review. PMID 29739477
In this connection, several B vitamins can be viewed as not only cofactors in muscle synthetic processes, but also as neurotrophic agents with involvements in both bioenergetic and trophic pathways. ...
In this connection, several B vitamins can be viewed as not only cofactors in muscle synthetic processes, but also as neurotrophic agents
Protective effects of the angiotensin II AT2 receptor agonist compound 21 in ischemic stroke: a nose-to-brain delivery approach
Bennion DM, et al. Clin Sci (Lond) 2018. PMID 29500223
N2B-administered C21 did not affect blood pressure or heart rate. Thus, these data provide proof-of-principle for the idea that N2B application of an AT(2) receptor agonist can exert neuroprotective actions when administered following ischemic stroke. Since N2B delivery of other agents has been shown to be effective in certain human central nervous system diseases, the N2B application of AT(2) receptor agonists may become a viable mode of delivering these neuroprotective agents for human ischemic stroke patients....
N2B-administered C21 did not affect blood pressure or heart rate. Thus, these data provide proof-of-principle for the idea that N2B a …
224 results
Jump to page
Feedback